ClinicalTrials.gg
RecruitingNCT07208825Updated Oct 23, 2026

The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.

An interventional study of rTMS and Basic physical therapy treatment in CRPS (Complex Regional Pain Syndromes), sponsored by Oulu University Hospital. Recruiting at 1 site in Finland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Oulu University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 23, 2026Start date movedStudy contact changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the study is to investigate and improve non-pharmacological rehabilitation methods for patients with Complex Regional Pain Syndrome (CRPS) to reduce pain and restore work and functional capacity to lower overall treatment costs. Current treatment methods offer limited rehabilitation potential for this challenging pain condition, so efforts should be made to raise the level of care and rehabilitation for a disease that often causes long-term and severe reductions in patients' functional and occupational abilities. CRPS patients almost always have to substantially reduce their work hours or withdrawn from the workforce for extended periods, and often permanently, increasing the urgency of strengthening rehabilitation approaches; a CRPS symptoms can end a patient's productivity for society. In addition, commonly used medications are a significant expense for both individuals and the healthcare system. CRPS rarely resolves fully, and even with extensive rehabilitation only a small proportion of patients regain sufficient improvement to return to work at a level of at least 60% capacity.

Participants will be recruited from the Department of Physical Medicine and Rehabilitation at Oulu University Hospital, where CRPS diagnostics for the Northern Ostrobothnia area are primarily conducted. The study will be carried out at OYS rehabilitation outpatient clinics. A total of 39 participants will be recruited into each of four study groups, for an overall sample size of 156 individuals. Each study group will receive repetitive transcranial magnetic stimulation (rTMS) at some point, and functional neurological rehabilitation will be combined with rTMS in varying ways (content and timing will differ between groups). All participants will receive basic CRPS rehabilitation (physiotherapy and occupational therapy) that is provided for all RPS patients, and the timing of this relative to rTMS will also be varied. Recruitment is planned to begin in a autumn 2025.

Read the detailed description

Complex Regional Pain Syndrome (CRPS) is a disabling and painful pain syndrome. It can be triggered by a very minor injury or a routine surgery, and the symptoms last much longer and are more difficult than the normal healing process would suggest. Symptoms of CRPS can include sensory and motor disorders, autonomic disorders, functional deficits, and major challenges in coping with daily activities. A multidisciplinary approach is required for treatment, even for several years.

Magnetic stimulation therapy (rTMS) has been used effectively to treat many types of pain conditions since the early 2000s. In rTMS therapy, a magnetic field is generated in the head area using an electromagnetic coil, which can affect the excitability level of the nerves in the stimulated area. rTMS therapy can irritate or calm the excitability threshold of the nerves. There are also some studies conducted with a small sample size on the treatment of CRPS using rTMS with relatively good results. The effectiveness of the treatment seems to emerge with a slight delay. The rTMS therapy may be used for CRPS patients.

The aim of the study is to investigate the significance of the timing of CRPS rehabilitation and functional neurological rehabilitation implemented at OYS in relation to rTMS treatment in alleviating symptoms and improving functional capacity in CRPS patients in 6, 12 and 36 months.

The study population consists of patients from the OYS physiatry who have been referred for assessment from primary health care or other OYS clinics to make or confirm a CRPS diagnosis. After a CRPS diagnosis is made, the patient's possible initiation of rTMS treatment is discussed in a multidisciplinary pain working group. Patients for whom rTMS treatment is considered a suitable form of treatment will be asked about their willingness to participate in a treatment study for CRPS patients. In addition, the patient's CRPS symptom must be in 1-3 limbs. CRPS that has spread to the body or more than 3 limbs is an exclusion criterion. The patient's CRPS must also have developed within less than 5 years, even if the diagnosis is only made during the initial assessment by the OYS physiatrist.

All those receiving rTMS treatment who understand Finnish will be connected to the rTMS digital treatment pathway, which will allow their situation and symptoms and the effectiveness of the treatment to be monitored as part of the clinical work. Before the start of rTMS treatment, a magnetic resonance imaging (MRI) of the head will be taken from the patient to plan the treatment, as the treatment area(s) will be planned using this individual "brain map". The standard rTMS treatment protocol includes a 2-week intensive treatment period (5 + 5 days) and then maintenance treatments once a month for 5 times, i.e. the total treatment period is 6 months. If necessary, the patient is contacted by phone. As long as the patient is on rTMS treatment, he or she is followed up on the digital treatment path and the patient's situation is also inquired about 3 and 6 months after the end of treatment via the digital treatment path. The material collected on the digital treatment path is used as part of the study data collection from the patients participating in the study. The digital treatment path has been implemented and all rTMS treatments are connected to the digital treatment path. There are several surveys on the digital treatment path which include the following:

Before the start of the rTMS treatment period: Jenkins sleep questionnaire, Beck Depression Inventory, quality of life questionnaire, visual analogue scale (pain questionnaire), amount of sleep and changes in well-being.

Patients entering the study will complete an informed consent form, after which they will be randomly assigned to one of four treatment groups. The randomization will be done in groups of 12 people, so that the different groups will have an even distribution of subjects throughout the study. The four treatment groups are:

  1. Group 1: Late initial rehabilitation and rTMS; CRPS initial rehabilitation (occupational and physiotherapy according to individual needs, approximately 10 outpatient visits) and rTMS treatment simultaneously after optimization of drug treatment simultaneously.
  2. Group 2: Neurological rehabilitation and rTMS; Neurologically focused initial rehabilitation group before the start of rTMS treatment and initial rehabilitation according to the normal treatment protocol.
  3. Group 3: Enhanced initial rehabilitation and late rTMS; CRPS initial rehabilitation and functional neurological rehabilitation initially and then rTMS treatment
  4. Group 4: OYS's so-called normal treatment; CRPS initial rehabilitation followed by rTMS treatment according to the current normal treatment protocol.

All study groups will receive minimum rehabilitation aimed at CRPS patients. All participants in the study will receive a period of rTMS treatment. Before randomization to groups, the severity of the patients' CRPS will be assessed using a dedicated scale. For a large proportion of CRPS patients, an rTMS treatment period is planned at the OYS unless there are contraindications to the treatment or previous examinations (head MRI). For all groups, drug treatment optimization will be implemented during the first 6 months of diagnosis.

The treatment of study group 1 includes drug treatment optimization during the first 6 months and then CRPS initial rehabilitation and rTMS treatment will be implemented simultaneously. rTMS treatment (6 months including a maximum of 15 treatment sessions) and CRPS initial rehabilitation (approx. 10 times) then begins at 6 months. CRPS initial rehabilitation includes a maximum of 10 treatment sessions together with a physiotherapist and/or occupational therapist, some of the appointments are joint appointments. Exercises and rehabilitation progress are selected individually. Initial rehabilitation includes the following areas and their emphasis areas are selected individually: assessment of rehabilitation goals, two-point discrimination, sleep guidance, relaxation training, GMI (including mirror therapy), balancing rest and activity (pacing), pressure garment assessment, therapeutic exercises, making activity/exercise plans, pain experience meter and hardening treatment. Initial rehabilitation usually lasts approx. 6 months.

In study group 2, the practice of functional neurology begins immediately after the CRPS diagnosis is made. rTMS treatment and CRPS initial rehabilitation (approx. 10x) then begin at 6 months at the latest. Functional neurological rehabilitation includes optimizing the neurophysiology of movement and pain and the cooperation of cranial nerves to improve brain plasticity, reduce the threat state experienced in the brain by inhibiting and activating specific nerve connections with individual exercises and thereby relieve pain. There are a total of 4-6 treatment sessions per subject at 3-6 week intervals, i.e. the functional neurology treatment period is carried out before the start of rTMS treatment. The first functional neurology rehabilitation visit is 90min (+ 30min recording time) and the following visits are 45min (+ 15min recording time).

In research group 3, CRPS initial rehabilitation and functional neurological are carried out during the first 6 months, and then an rTMS treatment period is carried out.

In research group 4, the starting point is the current rehabilitation of the OYS, i.e. initial rehabilitation is carried out during the first 6 months, and then an rTMS treatment period is carried out.

The number of subjects has been calculated with two main variables, pain and patient-specific functional scale (PTA), Taking into account a possible 20% dropout rate, the total number will be 156, i.e. 39 subjects in each group. The study will start in autumn 2025.

A multidisciplinary rehabilitation team will implement the rehabilitation of CRPS patients at OYS. Patients are selected for rTMS treatment by a multidisciplinary pain working group, which includes all healthcare professionals from the pain clinic and, for example, representation from clinical neurophysiology and psychiatry. This working group assesses patients who would potentially benefit from rTMS treatment and assesses whether the patient has any potential contraindications to the treatment or to MRI imaging of the head. In addition, the doctor who diagnosed the patient with CRPS at the physiatry clinic will also review any potential contraindications to treatment and imaging. There are no actual contraindications to rehabilitation and functional neurological rehabilitation. The patient must be able to commit to the exercises they receive from the rehabilitation.

The initial assessment is carried out at the physiatry outpatient clinic at the doctor's office, where a CRPS diagnosis is made and its severity is assessed. Basic data can be collected from all subjects via the digital path, so there is no need to order large numbers of additional surveys. In initial rehabilitation, an initial assessment is carried out by an occupational and physiotherapist. The same therapists make the same assessments again at the end of the initial rehabilitation (see the indicators section). Physiotherapists and occupational therapists are physiotherapists working at the physiatry outpatient clinic who have long-term experience in the rehabilitation of CRPS patients. The rehabilitation is a normal outpatient activity.

rTMS treatments are also carried out as normal outpatient activities in the clinical neurophysiology and physiatry clinics to the extent that equipment and staff capacity allow. rTMS treatments are carried out by a nurse who has received additional training in administering rTMS treatments as normal work at the KNF clinic. The MRI scans of the head are carried out according to the normal protocol. Functional neurological rehabilitation is only just beginning to spread from the world to Finland, and in this regard, there is only one expert in this field in Finland (OMT physiotherapist).

All those involved in the study are healthcare professionals and are subject to a confidentiality obligation. The patient's information is encoded under a numerical study code everywhere when transferring patient data outside the patient information system (SPSS, Excel) and only the people doing the administrative work of the study can access this information, as this information is behind password-protected storage systems.

Measures The main measures of the study are the patient-specific functional scale (PTA) and the pain questionnaire (VAS). In addition, patients will be measured on the rTMS digital therapy path for sleep quality (Jenkins sleep questionnaire), sleep quantity (open question), mood (BDI), fear-avoidance behavior (FABQ), mood (DEPS), self-efficacy (PSEQ), quality of life (15D), changes in well-being (open-ended question), fear of movement (TSK), left-right discrimination of the symptomatic limb and two-point discrimination ability at the beginning of the study, at 6 months and at 1 year. Thermal imaging of the CRPS limb will also be performed. In addition, the patient's medications and condition can be monitored during the study from patient document notes and via the rTMS digital treatment path.

The blinding of subjects or therapists is not possible to the therapies being implemented in the study, but it is possible to blind the persons providing the treatments to some of the measurement results (especially the person implementing the functional neurological rehabilitation).

02

Conditions studied

  • CRPS (Complex Regional Pain Syndromes)

Keywords

  • CRPS
  • GMI
  • Graded motor imaginary
  • Rehabilitation
  • Functional neurology
  • rTMS
  • medication
03

In context

Complex Regional Pain Syndromes

205 studies on the registry are indexed under Complex Regional Pain Syndromes; 55 are open to participants now.

This study's planned enrollment of 156 is above the median of 40 across 152 interventional studies indexed under Complex Regional Pain Syndromes.

Browse Complex Regional Pain Syndromes studies →

Lead sponsor

Oulu University Hospital is the lead sponsor of 40 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CRPS symptoms maximum of 5 year at the time of diagnosis (CRPS 1 and 2)
  • 18 to 70-year-old
  • rTMS treatment is granted by university hospital pain clinic (by multidisciplinary group)
  • Voluntary to participate into the study

Exclusion criteria

Exclusion Criteria:

  • CRPS symptoms started over five years ago (although diagnosed first time now)
  • No other outpatient/inpatient rehabilitation during the study rehabilitation period (insurance company or other third party)
  • Under 18-years-old of over 70-years-old
  • No eligible to rTMS treatment or for other reason rTMS treatment was not granted by university hospital pain clinic (by multidisciplinary group)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Active comparator
    Control group

    Optimizing medication (6mo) followed by rTMS and basic physical therapy rehabilitation (6mo)

    Device: rTMS · Other: Basic physical therapy treatment · Other: Functional neurology · Drug: Optimizing the medication

  • Experimental
    Early functional neurological rehabilitation

    Early functional neurological rehabilitation with optimizing medication (6mo) followed by rTMS and basic physical therapy rehabilitation (6mo)

    Device: rTMS · Other: Basic physical therapy treatment · Other: Functional neurology · Drug: Optimizing the medication

  • Experimental
    Early maximal rehabilitation

    Early functional neurological and physical therapy rehabilitation with optimizing medication (6mo) followed by rTMS (6mo)

    Device: rTMS · Other: Basic physical therapy treatment · Drug: Optimizing the medication

  • Other
    Basic treatment protocol

    Early physical therapy rehabilitation with optimizing medication (6mo) followed by rTMS (6mo)

    Device: rTMS · Other: Basic physical therapy treatment · Drug: Optimizing the medication

Interventions

  • DevicerTMS

    2 weeks starting period (10 treatment days) followed by 5 treatment once a month.

  • OtherBasic physical therapy treatment

    10 sessions with physical (or occupational) therapist with special education for treating CRPS

  • OtherFunctional neurology

    4 to 6 sessions with specialized OMT-physical therapist who will aim to improve the neurological deficits of the CRPS patient

  • Aim is to optimize the medication of the CRPS patient according the the medication guidelines

    Also known as: Medication

06

What researchers measure

Primary outcomes

  1. Patient specific functional scale (PSFS)

    Patient names three important tasks that are compromised by the CRPS and label them by number (from 0 to 10) according the to the ability to perform them at the day of evaluation. Higher the number, better the function (from 0 to 30)

    Time frame: Enrollment, 6, 12 and 36 months.

  2. Visual analog scale (VAS)

    Participant is asked to mark with a vertical line the pain experienced during the day of evaluation into the 10cm horizontal line.

    Time frame: Enrollment, 6, 12 and 36 months

Secondary outcomes

  1. Jenkis sleep questionnaire

    a four-item self-report instrument designed to efficiently screen for the frequency and intensity of common sleep disturbances

    Time frame: Enrollment, 6, 12 and 36 months. During the rTMS treatment

  2. Amount of sleep

    Open question on average hours of sleep during the last week

    Time frame: Enrollment, 6, 12 and 36 months. During the rTMS treatment

  3. Beck Depression Inventory

    a 21-item, self-report questionnaire designed to screen for and measure the severity of depression in adults and adolescents

    Time frame: Enrollment, 6, 12 and 36 months

  4. DEPS

    10 item depression questionnaire

    Time frame: Enrollment, 6, 12 and 36 months

  5. Pain Self-Efficacy Questionnaire (PSEQ)

    a 10-item questionnaire developed to assess the confidence people with ongoing pain have in performing activities while in pain

    Time frame: Enrollment, 6, 12 and 36 months

  6. 15D

    A generic, comprehensive (15-dimensional), self-administered instrument for measuring Health Related Quality of Life among adults

    Time frame: Enrollment, 6, 12 and 36 months

Other outcomes

  1. General well-being question

    Open question

    Time frame: ENrollment, 6, 12 and 36 months

  2. Tampa Scale of Kinesiophobia

    a 17-item self-report questionnaire designed to measure fear of movement or re-injury, particularly in patients with chronic pain

    Time frame: Enrollment, 6, 12 and 36 months

  3. Right-left discrimination

    the ability to differentiate between the left and right sides of one's body and the external world (test is performed with iPad)

    Time frame: Enrollment, 6, 12 months

  4. Two-point discrimination

    a neurological assessment of tactile spatial acuity, measuring the ability to perceive two simultaneous points of touch as separate rather than one (affected and non-affected limb)

    Time frame: Enrollment, 6, 12 months

07

Study locations

1 of 1 sites recruiting
  • Oulu University Hospital, Pain Clinic
    Oulu, North Ostrobothnia 90100, Finland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — This is not decided yet

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.

Of 64 non-industry interventional studies with no phase under Complex Regional Pain Syndromes, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 62 months is above that.

Counting every sponsor, half of 65 studies reached it within 24 months; a quarter within 14 and three quarters within 60.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Oct 5, 2025was Sep 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2033
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2025→Oct 5, 2025 (actual)
Oct 23, 2026
Contact
Study contact changed: o•••@gmail.com · •••2129→o•••@gmail.com · •••2129; o•••@gmail.com · •••2129→o•••@gmail.com · •••2129. See the current contact
Oct 23, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Oulu University Hospital, Pain Clinic · Oulu, FinlandContact o•••@gmail.com · •••2129→o•••@gmail.com · •••2129Contact o•••@gmail.com · •••2129→o•••@gmail.com · •••2129Contact person changed (no phone or email listed)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Sep 30, 2025→Oct 5, 2025 (now actual)
    Contact Study contact changed: o•••@gmail.com · •••2129→o•••@gmail.com · •••2129; o•••@gmail.com · •••2129→o•••@gmail.com · •••2129. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Oulu University Hospital, Pain Clinic · Oulu, FinlandContact o•••@gmail.com · •••2129→o•••@gmail.com · •••2129Contact o•••@gmail.com · •••2129→o•••@gmail.com · •••2129Contact person changed (no phone or email listed)
    + 6 other changes: index terms, verification date, responsible party, description, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07208825
Lead sponsor
Oulu University Hospital
Responsible party
Jani Takatalo (Associate Chief Physician, Pain Clinic, Oulu University Hospital) — Principal investigator
First posted
Oct 6, 2025
Start date
Oct 5, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Oct 23, 2026

Study contacts

Jani M Takatalo, PhD, MD
Contact
oysfysiatriatutkimus@gmail.com
+358 8 315 2129
Juhani Määttä, Docent, MD
Contact
oysfysiatriatutkimus@gmail.com
+358 8 315 2129
Jani M Takatalo, PhD, MD
principal investigator · Oulu University Hospital, Pain Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medication

Start the discussion